```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable scientific substance extensively used in cardiovascular studies . This Fab fragment primarily targets the glycoprotein IIb/IIIa binding site on thrombocytes , inhibiting platelet aggregation . Consequently , it's commonly investigated as a technique to copyrightine the pathways underlying coagulation and to assess the performance of antithrombotic medications . Supply is typically controlled to institutional settings.
```
Abciximab Drug Research: Utilizing The C7E3 Fragment and The 143653-53-6 Substance in Scientific Assessments
Ongoing studies into abciximab, a antiplatelet agent, frequently utilizes the monoclonal antigen C7E3 and the chemical compound identified as 143653-53-6. These reagents are crucial for investigating abciximab's mechanism of action, evaluating its therapeutic effect in different patient populations, and elucidating potential predictors of patient outcome. Further exploration leveraging these particular reagents is expected to yield valuable information for improving therapeutic strategies concerning cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet here activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Potential Opportunities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 and C7E3
Recent studies suggest that Abciximab (identified as 143653-53-6) presents significant investigative value, particularly when paired with the antibody fragment. Preliminary observations indicated that this pairing could enhance clinical results in several cardiovascular settings. Further exploration is directed on defining the precise process of interaction between this inhibitor and C7E3, involving study of thrombocyte clumping and arterial safeguarding.
- Current study work seek to optimize dosing strategies.
- Laboratory systems are are being applied to further validate the theories.
- Human trials will be required to completely determine clinical effectiveness.
```
Abciximab (C7E3) for Research: Purity and Details (143653-53-6)
Researchers seeking abciximab for in vitro studies should meticulously assess integrity and defined specifications . The compound is typically offered as a freeze-dried powder and detailed analytical data including verification by LC-MS, potency assays, and endotoxin testing are available. Confirm the manufacturer's documentation outlines defined limits for related substances and fulfills relevant quality control standards .
Pharmaceutical-Grade C7E3 Details & Availability
Acquiring analytical-grade Abciximab, specifically referencing the compound C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its manufacturer. This glycoprotein is widely utilized in in vitro experiments, particularly those related to platelet aggregation and thrombosis . Available suppliers offer this material in varying quantities , typically ranging from mg to substantial commercial supplies. Please advise reviewing the documentation of testing to verify integrity and applicability for your specific use . Moreover, check the expiration date before procuring to maintain maximum efficacy .
- Typical Purity: >95%
- Keeping Conditions: -20°C in suitable conditions
- Application : Platelet Aggregation Blocking Studies